Life sciences: the most expensive buildout in real estate, for the weakest credit

Everything on the real estate core applies to lab space. What’s specific here is a collision the core page’s logic doesn’t face anywhere else: the most expensive tenant improvements in real estate, routinely handed to tenants with the weakest credit profiles in real estate.

The buildout math: TI-as-loan at its most extreme

The core page frames a tenant improvement allowance as a loan the landlord recoups through rent. Lab space is that idea at maximum stress. Specialized HVAC running far more air changes than office, fume hoods, vibration isolation, redundant power, chemical waste handling: lab buildout runs multiples of office cost per foot.

And the borrower on this loan is often a venture-backed biotech with no revenue, a cash runway measured in quarters, and a business that lives or dies on trial results the landlord can’t underwrite.

The structuring consequences follow directly. Security sized to office norms is wrong here: letters of credit several times an office deal’s size, sometimes with burn-down schedules tied to the tenant’s actual funding milestones rather than mere passage of time. And the default-recovery language the core page says every allowance needs becomes the single most negotiated economic term in the lease, because the unamortized balance at risk is that much larger.

Re-leasing risk: how specialized is this buildout, really

The saving grace is that generic lab improvements, the air handling, the power, the basic wet-lab infrastructure, hold value for the next lab tenant in a way one tenant’s office buildout never does. The trap is buildouts specialized past that point, GMP manufacturing suites, vivarium space, configurations only the departing tenant’s exact science needed.

A landlord funding a buildout should price which category they’re funding. Generic lab shell is a durable asset. Tenant-specific configuration is the core page’s build-to-suit problem wearing a lab coat, and the lease term or termination payment should be sized to it.

Sale-leasebacks: the tenant selling you the building needs the money

A recurring life sciences transaction: a biotech that owns its facility sells it and leases it back, converting real estate into runway. The buyer gets a long lease from a tenant whose need for the transaction is itself the disclosure.

The core page’s line applies with an edge here, the lease is the asset, and this lease’s credit is a clinical pipeline. Underwriting the deal means underwriting the tenant’s cash position and funding prospects the way a venture investor would, not the way a net-lease buyer reads an investment-grade tenant’s rating.

Operating Agreement Specifics: The Credit Package Threshold

Because each lab lease pairs a huge landlord investment with fragile tenant credit, the security package on any major lease, letter of credit size, burn-down triggers, guaranty terms, is a real economic decision, not lease boilerplate.

The operating agreement should require member approval of the credit package on leases above a defined buildout commitment, separately from approving the lease’s headline rent. The rent is not where these deals go wrong.

Operating Agreement Specifics: Specialization Sign-Off

The operating agreement should distinguish generic lab improvements from tenant-specific specialization, and require a higher approval threshold for funding the second category.

One heading, one decision: members should have to say yes, specifically, before the entity funds improvements only one tenant on earth can use.

Where this hands off

The TI-as-loan framing and the default-recovery logic live on the real estate core. The build-to-suit parallel lives on industrial. This page’s job was narrower: naming the credit-against-buildout collision that defines this asset class, and sizing the standard protections to it.